Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery.

Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu ® Clinical trial with AVA6103 is expected to be initiated ...

Explore the World ADC Conference highlights on antibody-drug conjugates and their impact on cancer therapy and clinical ...

Because of advances in linker conjugation chemistry and our understanding of the ADC mechanism of action in vivo, an increasing breadth of anticancer agents are now being incorporated in newer ADC ...

Avacta's preCision platform is a proprietary payload delivery system designed to concentrate highly potent payloads in the tumour microenvironment while sparing normal tissues.

BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data ...

Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.

LONDON and PHILADELPHIA - February 24, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology ...